Explore how biomarkers can predict BCG failure in high-risk bladder cancer, aiding in personalized treatment strategies.

The FDA has approved atezolizumab combined with chemotherapy for treating stage III dMMR colon cancer, enhancing post-surgery treatment options.

A study suggests that a reduced dose of enfortumab vedotin may lower toxicity in older patients with urothelial carcinoma, ...

Learn how intelligent medical records enhance patient care, streamline workflows, and improve healthcare outcomes through ...

Explore a comparative study on ESR1 mutation testing using dPCR and NGS. Understand the strengths and applications of each ...

Explore the FDA fast track oncology drugs granted in September 2026, advancing treatments for various cancer types.

At WCLC 2026, three thoracic oncologists discuss first-line regimen selection, subcutaneous dosing, dermatologic prophylaxis, and dose modifications in EGFR-mutant NSCLC. Subcutaneous amivantamab has ...

On Oct. 2, the U.S. Food and Drug Administration (FDA) approved pirtobrutinib (Jaypirca) for adults with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who ...

Recent headlines on leadership appointments, executive transitions, and notable recognitions spotlight the leaders helping to shape oncology research, patient care, and cancer organizations. MD ...

Bundled payment models can offer employers more predictable cancer costs, but implementing them in community oncology can be complicated by financial risk and administrative demands. At the 2026 ...

Community oncology practices can point to advantages such as care closer to home, greater affordability, and a more ...